{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T21:21:40Z","timestamp":1787692900142,"version":"build-2784847793"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,25]]},"DOI":"10.7759\/cureus.115175","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T21:07:30Z","timestamp":1787692050000},"source":"Crossref","is-referenced-by-count":0,"title":["Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer: Distinguishing Prophylactic and Therapeutic Roles Within Contemporary Multimodal Management"],"prefix":"10.7759","author":[{"given":"Saqer","family":"Dayis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Alshaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roaa","family":"Alosaimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saud","family":"Almutairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebaa","family":"Jamjoom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turki","family":"Alotaibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"Al-Hajeili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouki","family":"Bazarbashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Aseafan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28373","article-title":"Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors","volume":"134","author":"Thomassen I","year":"2014","unstructured":"Thomassen I, van Gestel YR, van Ramshorst B, et al.. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer. 2014, 134:622-8. 10.1002\/ijc.28373","journal-title":"Int J Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2013.10.019","article-title":"Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials","volume":"40","author":"Coccolini F","year":"2014","unstructured":"Coccolini F, Cotte E, Glehen O, et al.. Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. Eur J Surg Oncol. 2014, 40:12-26. 10.1016\/j.ejso.2013.10.019","journal-title":"Eur J Surg Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2025.109731","article-title":"Management of peritoneal gastric metastasis: an update","volume":"51","author":"Mariani A","year":"2025","unstructured":"Mariani A, Triantafyllou E, Kepenekian V, Zaanan A, Glehen O, Karoui M. Management of peritoneal gastric metastasis: an update. Eur J Surg Oncol. 2025, 51:109731. 10.1016\/j.ejso.2025.109731","journal-title":"Eur J Surg Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.5230\/jgc.2020.20.e15","article-title":"Recent advances in hyperthermic intraperitoneal chemotherapy for gastric cancer","volume":"20","author":"Chia DK","year":"2020","unstructured":"Chia DK, So JB. Recent advances in hyperthermic intraperitoneal chemotherapy for gastric cancer. J Gastric Cancer. 2020, 20:115-26. 10.5230\/jgc.2020.20.e15","journal-title":"J Gastric Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11051456","article-title":"HIPEC in peritoneal metastasis of gastric origin: a systematic review of regimens and techniques","volume":"11","author":"Gronau F","year":"2022","unstructured":"Gronau F, Feldbruegge L, Oberwittler F, et al.. HIPEC in peritoneal metastasis of gastric origin: a systematic review of regimens and techniques. J Clin Med. 2022, 11:1456. 10.3390\/jcm11051456","journal-title":"J Clin Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02867","article-title":"Effect of hyperthermic intraperitoneal chemotherapy on cytoreductive surgery in gastric cancer with synchronous peritoneal metastases: the phase III GASTRIPEC-I trial","volume":"42","author":"Rau B","year":"2024","unstructured":"Rau B, Lang H, Koenigsrainer A, et al.. Effect of hyperthermic intraperitoneal chemotherapy on cytoreductive surgery in gastric cancer with synchronous peritoneal metastases: the phase III GASTRIPEC-I trial. J Clin Oncol. 2024, 42:146-56. 10.1200\/JCO.22.02867","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(26)00144-0","article-title":"Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limited peritoneal metastases (PERISCOPE II): final results of a multicentre, randomised, controlled, phase 3 trial after an unplanned commissioned interim analysis","volume":"27","author":"Quik JS","year":"2026","unstructured":"Quik JS, Vollebergh MA, Retel VP, et al.. Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limited peritoneal metastases (PERISCOPE II): final results of a multicentre, randomised, controlled, phase 3 trial after an unplanned commissioned interim analysis. Lancet Oncol. 2026, 27:1031-42. 10.1016\/S1470-2045(26)00144-0","journal-title":"Lancet Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham D","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, et al.. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006, 355:11-20. 10.1056\/NEJMoa055531","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial","volume":"393","author":"Al-Batran SE","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, et al.. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019, 393:1948-57. 10.1016\/S0140-6736(18)32557-1","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0022","article-title":"Gastric cancer, version 2.2025, NCCN Clinical Practice Guidelines in Oncology","volume":"23","author":"Ajani JA","year":"2025","unstructured":"Ajani JA, D'Amico TA, Bentrem DJ, et al.. Gastric cancer, version 2.2025, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2025, 23:169-91. 10.6004\/jnccn.2025.0022","journal-title":"J Natl Compr Canc Netw"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2503701","article-title":"Perioperative durvalumab in gastric and gastroesophageal junction cancer","volume":"393","author":"Janjigian YY","year":"2025","unstructured":"Janjigian YY, Al-Batran SE, Wainberg ZA, et al.. Perioperative durvalumab in gastric and gastroesophageal junction cancer. N Engl J Med. 2025, 393:217-30. 10.1056\/NEJMoa2503701","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.096","article-title":"LBA81 final overall survival and the association of pathological outcomes with event-free survival in MATTERHORN: a randomised, phase III study of durvalumab plus FLOT in resectable gastric\/gastroesophageal junction cancer","volume":"36","author":"Tabernero J","year":"2025","unstructured":"Tabernero J, Janjigian YY, Al-Batran SE, et al.. LBA81 final overall survival and the association of pathological outcomes with event-free survival in MATTERHORN: a randomised, phase III study of durvalumab plus FLOT in resectable gastric\/gastroesophageal junction cancer. Ann Oncol. 2025, 36:81. 10.1016\/j.annonc.2025.09.096","journal-title":"Ann Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang YJ","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, et al.. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010, 376:687-7. 10.1016\/S0140-6736(10)61121-X","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02033-0","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian YY","year":"2023","unstructured":"Janjigian YY, Kawazoe A, Ya\u00f1ez P, et al.. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023, 402:2197-208. 10.1016\/S0140-6736(23)02033-0","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2517729","article-title":"Zanidatamab with and without tislelizumab in HER2-positive gastroesophageal cancer","volume":"394","author":"Shitara K","year":"2026","unstructured":"Shitara K, Elimova E, Liu T, et al.. Zanidatamab with and without tislelizumab in HER2-positive gastroesophageal cancer. N Engl J Med. 2026, 394:2002-14. 10.1056\/NEJMoa2517729","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-07450-4","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer with peritoneal carcinomatosis: multicenter study of Spanish Group of Peritoneal Oncologic Surgery (GECOP)","volume":"26","author":"Manzanedo I","year":"2019","unstructured":"Manzanedo I, Pereira F, Rihuete Caro C, et al.. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer with peritoneal carcinomatosis: multicenter study of Spanish Group of Peritoneal Oncologic Surgery (GECOP). Ann Surg Oncol. 2019, 26:2615-21. 10.1245\/s10434-019-07450-4","journal-title":"Ann Surg Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01688","article-title":"Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis","volume":"37","author":"Bonnot PE","year":"2019","unstructured":"Bonnot PE, Piessen G, Kepenekian V, et al.. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J Clin Oncol. 2019, 37:2028-40. 10.1200\/JCO.18.01688","journal-title":"J Clin Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8101685","article-title":"Prophylactic hyperthermic intraperitoneal chemotherapy for gastric cancer: a systematic review","volume":"8","author":"Brenkman HJ","year":"2019","unstructured":"Brenkman HJ, P\u00e4eva M, van Hillegersberg R, Ruurda JP, Haj Mohammad N. Prophylactic hyperthermic intraperitoneal chemotherapy for gastric cancer: a systematic review. J Clin Med. 2019, 8:1685. 10.3390\/jcm8101685","journal-title":"J Clin Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6125-z","article-title":"Prophylactic HIPEC with radical D2 gastrectomy improves survival and peritoneal recurrence rates for locally advanced gastric cancer: personal experience from a randomized case control study","volume":"19","author":"Beeharry MK","year":"2019","unstructured":"Beeharry MK, Zhu ZL, Liu WT, Yao XX, Yan M, Zhu ZG. Prophylactic HIPEC with radical D2 gastrectomy improves survival and peritoneal recurrence rates for locally advanced gastric cancer: personal experience from a randomized case control study. BMC Cancer. 2019, 19:932. 10.1186\/s12885-019-6125-z","journal-title":"BMC Cancer"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S249838","article-title":"Lobaplatin in prophylactic hyperthermic intraperitoneal chemotherapy for advanced gastric cancer: safety and efficacy profiles","volume":"12","author":"Zhong Y","year":"2020","unstructured":"Zhong Y, Zhang J, Bai X, et al.. Lobaplatin in prophylactic hyperthermic intraperitoneal chemotherapy for advanced gastric cancer: safety and efficacy profiles. Cancer Manag Res. 2020, 12:5141-6. 10.2147\/CMAR.S249838","journal-title":"Cancer Manag Res"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.995618","article-title":"Lobaplatin-based prophylactic hyperthermic intraperitoneal chemotherapy for T4 gastric cancer patients: a retrospective clinical study","volume":"13","author":"Zhong Y","year":"2023","unstructured":"Zhong Y, Kang W, Hu H, Li W, Zhang J, Tian Y. Lobaplatin-based prophylactic hyperthermic intraperitoneal chemotherapy for T4 gastric cancer patients: a retrospective clinical study. Front Oncol. 2023, 13:995618. 10.3389\/fonc.2023.995618","journal-title":"Front Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s00423-021-02137-5","article-title":"Survival advantage of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced gastric cancer: experience from a Western tertiary referral center","volume":"406","author":"Rosa F","year":"2021","unstructured":"Rosa F, Galiandro F, Ricci R, et al.. Survival advantage of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced gastric cancer: experience from a Western tertiary referral center. Langenbecks Arch Surg. 2021, 406:1071-80. 10.1007\/s00423-021-02137-5","journal-title":"Langenbecks Arch Surg"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.gassur.2024.04.007","article-title":"Prophylaxis and treatment of peritoneal carcinomatosis of gastric origin using hyperthermic intraperitoneal chemotherapy: a systematic review and meta-analysis of randomized trials","volume":"28","author":"Stefano M","year":"2024","unstructured":"Stefano M, Perrina D, Vallicelli C, et al.. Prophylaxis and treatment of peritoneal carcinomatosis of gastric origin using hyperthermic intraperitoneal chemotherapy: a systematic review and meta-analysis of randomized trials. J Gastrointest Surg. 2024, 28:1185-93. 10.1016\/j.gassur.2024.04.007","journal-title":"J Gastrointest Surg"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.4103\/hemoncstem.hemoncstem-D-25-00040","article-title":"Characteristic and clinical outcomes of localized gastric cancer: a real-world experience","volume":"18","author":"Aljuhani A","year":"2025","unstructured":"Aljuhani A, Aseafan M, Sheikh A, Alhanash A, Alshamsan B, Elhassan T, Bazarbashi S. Characteristic and clinical outcomes of localized gastric cancer: a real-world experience. Hematol Oncol Stem Cell Ther. 2025, 18:140-5. 10.4103\/hemoncstem.hemoncstem-D-25-00040","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-183","article-title":"GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study","volume":"14","author":"Glehen O","year":"2014","unstructured":"Glehen O, Passot G, Villeneuve L, et al.. GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study. BMC Cancer. 2014, 14:183. 10.1186\/1471-2407-14-183","journal-title":"BMC Cancer"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-011-1631-5","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial","volume":"18","author":"Yang XJ","year":"2011","unstructured":"Yang XJ, Huang CQ, Suo T, et al.. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011, 18:1575-81. 10.1245\/s10434-011-1631-5","journal-title":"Ann Surg Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/525318-hyperthermic-intraperitoneal-chemotherapy-in-gastric-cancer-distinguishing-prophylactic-and-therapeutic-roles-within-contemporary-multimodal-management","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T21:07:32Z","timestamp":1787692052000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/525318-hyperthermic-intraperitoneal-chemotherapy-in-gastric-cancer-distinguishing-prophylactic-and-therapeutic-roles-within-contemporary-multimodal-management"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.115175","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,25]]}}}